Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials
Background: Although there have been network meta-analyses (NMAs) regarding the efficacy and safety of targeted immunotherapy for psoriatic arthritis, most of them primarily focus on biologics. However, small molecules and biologics have many differences in properties and onset time. This NMA put em...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Musculoskeletal Disease |
| Online Access: | https://doi.org/10.1177/1759720X241305459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850114795251957760 |
|---|---|
| author | Ya-Chu Tsai Chen-Yiu Hung Tsen-Fang Tsai |
| author_facet | Ya-Chu Tsai Chen-Yiu Hung Tsen-Fang Tsai |
| author_sort | Ya-Chu Tsai |
| collection | DOAJ |
| description | Background: Although there have been network meta-analyses (NMAs) regarding the efficacy and safety of targeted immunotherapy for psoriatic arthritis, most of them primarily focus on biologics. However, small molecules and biologics have many differences in properties and onset time. This NMA put emphasis on small molecule drugs and incorporates medications including upadacitinib and deucravacitinib, which have been less compared previously. Objective: To compare the efficacy and safety of small molecule drugs (apremilast, deucravacitinib, tofacitinib, and upadacitinib) in active psoriatic arthritis (PsA) using NMA. Design: This study was conducted and reported following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension Statement for Network Meta-Analyses (PRISMA-NMA), with relevant articles identified through searches across electronic databases. Data sources and methods: Databases including PubMed, Cochrane Library, and ClinicalTrial.gov were searched. Randomized controlled trials (RCTs) of targeted synthetic small molecules for PsA controlled by either placebo or active comparators within weeks 12–16 were eligible. A frequentist framework and a random-effect model were employed for the analysis. The revised Cochrane risk-of-bias tool for RCTs was used to assess the quality of the enrolled studies. Results: A total of 9 RCTs involving 3699 patients were analyzed. Apremilast 30 mg bid, deucravacitinib 6 mg and 12 mg qd, tofacitinib 5 mg bid, and upadacitinib 15 mg qd all demonstrated superior efficacy over placebo in achieving American College of Rheumatology (ACR) 20/50/70, Psoriasis Area and Severity Index (PASI) 75, and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores at weeks 12–16. When compared to adalimumab, upadacitinib achieved borderline superiority in PASI 75 at week 12 (risk ratio (RR) = 1.20, 95% confidence interval (CI): 1.02–1.40). Among the four medications studied, only deucravacitinib showed significantly better HAQ-DI scores compared to apremilast (RR = −0.16, 95% CI: −0.29 to −0.02), with no statistically significant differences observed in other parameters. Conclusion: All four small molecule oral medications exhibited superior efficacy to placebo and comparable safety profiles. Across different assessment criteria, including ACR 50, ACR 70, PASI 75, or HAQ-DI, deucravacitinib 12 mg and upadacitinib consistently ranked in the top two positions. |
| format | Article |
| id | doaj-art-29d2f6db548244ee91ba382b2f1cc0d7 |
| institution | OA Journals |
| issn | 1759-7218 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Musculoskeletal Disease |
| spelling | doaj-art-29d2f6db548244ee91ba382b2f1cc0d72025-08-20T02:36:45ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182024-12-011610.1177/1759720X241305459Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trialsYa-Chu TsaiChen-Yiu HungTsen-Fang TsaiBackground: Although there have been network meta-analyses (NMAs) regarding the efficacy and safety of targeted immunotherapy for psoriatic arthritis, most of them primarily focus on biologics. However, small molecules and biologics have many differences in properties and onset time. This NMA put emphasis on small molecule drugs and incorporates medications including upadacitinib and deucravacitinib, which have been less compared previously. Objective: To compare the efficacy and safety of small molecule drugs (apremilast, deucravacitinib, tofacitinib, and upadacitinib) in active psoriatic arthritis (PsA) using NMA. Design: This study was conducted and reported following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension Statement for Network Meta-Analyses (PRISMA-NMA), with relevant articles identified through searches across electronic databases. Data sources and methods: Databases including PubMed, Cochrane Library, and ClinicalTrial.gov were searched. Randomized controlled trials (RCTs) of targeted synthetic small molecules for PsA controlled by either placebo or active comparators within weeks 12–16 were eligible. A frequentist framework and a random-effect model were employed for the analysis. The revised Cochrane risk-of-bias tool for RCTs was used to assess the quality of the enrolled studies. Results: A total of 9 RCTs involving 3699 patients were analyzed. Apremilast 30 mg bid, deucravacitinib 6 mg and 12 mg qd, tofacitinib 5 mg bid, and upadacitinib 15 mg qd all demonstrated superior efficacy over placebo in achieving American College of Rheumatology (ACR) 20/50/70, Psoriasis Area and Severity Index (PASI) 75, and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores at weeks 12–16. When compared to adalimumab, upadacitinib achieved borderline superiority in PASI 75 at week 12 (risk ratio (RR) = 1.20, 95% confidence interval (CI): 1.02–1.40). Among the four medications studied, only deucravacitinib showed significantly better HAQ-DI scores compared to apremilast (RR = −0.16, 95% CI: −0.29 to −0.02), with no statistically significant differences observed in other parameters. Conclusion: All four small molecule oral medications exhibited superior efficacy to placebo and comparable safety profiles. Across different assessment criteria, including ACR 50, ACR 70, PASI 75, or HAQ-DI, deucravacitinib 12 mg and upadacitinib consistently ranked in the top two positions.https://doi.org/10.1177/1759720X241305459 |
| spellingShingle | Ya-Chu Tsai Chen-Yiu Hung Tsen-Fang Tsai Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials Therapeutic Advances in Musculoskeletal Disease |
| title | Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of small molecule oral medications for psoriatic arthritis: a network meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of small molecule oral medications for psoriatic arthritis a network meta analysis of randomized controlled trials |
| url | https://doi.org/10.1177/1759720X241305459 |
| work_keys_str_mv | AT yachutsai efficacyandsafetyofsmallmoleculeoralmedicationsforpsoriaticarthritisanetworkmetaanalysisofrandomizedcontrolledtrials AT chenyiuhung efficacyandsafetyofsmallmoleculeoralmedicationsforpsoriaticarthritisanetworkmetaanalysisofrandomizedcontrolledtrials AT tsenfangtsai efficacyandsafetyofsmallmoleculeoralmedicationsforpsoriaticarthritisanetworkmetaanalysisofrandomizedcontrolledtrials |